2026 ICD-10-CM Diagnosis Code Z19.2Hormone resistant malignancy status

ICD-10-CM Codes›Z00–Z99›Z19›Z19

ICD-10-CM Z19.2
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

Z19.2 is a billable ICD-10-CM diagnosis code for hormone resistant malignancy status. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 951. The code is not accepted as a principal diagnosis by the Medicare Code Editor and exempt from POA reporting. Coders also document this condition as primary malignant hormone-refractory neoplasm of prostate. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Genetic susceptibility to disease; and Malignant neoplasm, unspecified.

Code Identity

ICD-10-CM Code
Z19.2
Billable Status
Yes — Valid for Submission
Code Describes
Hormone resistant malignancy status
Short Description
Hormone resistant malignancy status
Same as the full description in the CMS dataset.
Parent Code
Z19
Hormone sensitivity malignancy status

Code Classification

ChapterZ00–Z99Factors influencing health status and contact with health services
SectionZ19Hormone sensitivity malignancy status
CategoryZ19Hormone sensitivity malignancy status
This CodeZ19.2Hormone resistant malignancy status

Code EditsBilling

Medicare Code Editor checks that affect claim validity for Z19.2.

Unacceptable principal diagnosis
There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.

Present on Admission (POA)Billing

Z19.2 is exempt from POA reporting on inpatient claims to general acute care hospitals. Review the other POA exempt codes in Hormone sensitivity malignancy status (Z19).

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Primary malignant hormone-refractory neoplasm of prostate
  • Primary malignant neoplasm of prostate

Tabular List NotesGuidance

Coding notes and annotation back-references applicable to this code.

Inclusion Terms

  • Castrate resistant prostate malignancy status

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR FAC029
Genetic susceptibility to disease
Default principal diagnosis: inpatient No · outpatient No
CCSR NEO071
Malignant neoplasm, unspecified
Default principal diagnosis: inpatient No · outpatient No

Convert Z19.2 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
No Map There is no ICD-9 equivalent for this code.

Code History & ChangesHistory

Replacement Z19.2 replaces the following previously assigned code(s):

  • R97.8 - Other abnormal tumor markers
FY 2019AddedAdded to the ICD-10-CM code setEffective October 1, 2018.
FY 2020–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About Z19.2Overview

What is the ICD-10 code for hormone resistant malignancy status?

The ICD-10-CM code for hormone resistant malignancy status is Z19.2 (sometimes written as Z192). It is billable on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

Is Z19.2 (Hormone sensitivity malignancy status) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report hormone resistant malignancy status on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What MS-DRG does Z19.2 group to?

On inpatient claims, hormone resistant malignancy status maps to MS-DRG 951 (other Factors Influencing Health Status), which carries a relative weight of 0.556. Higher weights mean higher Medicare reimbursement.

Can Z19.2 be a principal diagnosis?

No. The Medicare Code Editor rejects this code as a principal diagnosis because hormone resistant malignancy status describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.

Is Z19.2 exempt from POA reporting?

Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for hormone resistant malignancy status on inpatient claims. The code appears in the Hormone sensitivity malignancy status (Z19) range of the CMS exempt list.